Login to Your Account

Eravacycline phase III lead-in data 'IGNITE' Tetraphase investors

By Marie Powers
Staff Writer

Wednesday, September 3, 2014
Following Tuesday's market close, Tetraphase Pharmaceuticals Inc. reported top-line data from the lead-in portion of its two-part phase III IGNITE 2 trial, showing that both I.V.-to-oral dosing regimens of eravacycline compared favorably to comparator drug levofloxacin to treat complicated urinary tract infections.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription